Hepatitis B virus encoded X antigen ( HBxAg ) may contribute to the development of hepatocellular carcinoma ( HCC ) by up -or downregulating the expression of cellular genes that promote cell growth and survival. To test this hypothesis, HBxAg -positive and -negative HepG2 cells were constructed, and the patterns of cellular gene expression compared by polymerase chain reaction select cDNA subtraction. The full -length clone of one of these upregulated genes ( URG ), URG4, encoded a protein of about 104 kDa. URG4 was strongly expressed in hepatitis B -infected liver and in HCC cells, where it costained with HBxAg, and was weakly expressed in uninfected liver, suggesting URG4 was an effector of HBxAg in vivo. Overexpression of URG4 in HepG2 cells promoted hepatocellular growth and survival in tissue culture and in soft agar, and accelerated tumor development in nude mice. Hence, URG4 may be a natural effector of HBxAg that contributes importantly to multistep hepatocarcinogenesis.
Introduction
Hepatitis B virus ( HBV ) is a major etiologic agent associated with chronic liver diseases, such as hepatitis, cirrhosis, and hepatocellular carcinoma ( HCC ) [ 1, 2 ] . HCC is among the most common tumor types worldwide, with more than 370,000 cases diagnosed annually, and a survival rate of < 3% over 5 years [ 2, 3 ] . The relative risk of HBV carriers developing HCC is in excess of 100, suggesting that the relationship between HBV and HCC is one of tightest between a virus and a human cancer [ 2, 4 ] .
The molecular mechanisms underlying this high risk for tumor development are incompletely understood, although the chronic carrier state and the progression of chronic liver disease are major risk factors [1] [2] [3] [4] [5] . HBV also encodes a protein known as hepatitis Bx antigen ( HBxAg ) that appears to participate in the development of HCC [ 6, 7 ] . For example, the X gene of HBV is commonly integrated into host DNA at many, apparently random sites [ 8 ] . Many of these integration events result in the generation of X region mRNA [ 9, 10 ] and HBxAg [ 11 -14 ] in infected liver and tumor. HBxAg also directly correlates with the severity of liver disease [ 15 ] . In some strains of X transgenic mice with sustained high levels of HBxAg, HCC develops [ 16, 17 ] . X region DNA from the virus genome and from HCC nodules have been shown to transform a liver cell line [ 18, 19 ] . These independent lines of evidence suggest that HBxAg contributes importantly to hepatocarcinogenesis.
HBxAg is a trans -activating protein [ 20 ] , and it has been proposed that the effects of HBxAg on the transcription of cellular genes underlies the mechanism whereby HBV contributes to the high risk of HCC [ 6, 7 ] . Interestingly, HBxAg trans -activation appears to be carried out through the stimulation of multiple cytoplasmic signal transduction pathways, such as those involving ras [ 21 ] , nuclear factor kappa B (NF-B ) [ 22 ] , activating protein -1 ( AP -1 ) [ 23 ] , and janus kinase ( JAK ) / signal transducer and activator of transcription ( STAT ) [ 24 ] . In the nucleus, HBxAg trans -activation appears to involve the binding of HBxAg to a variety of transcription factors, such as a subunit of RNA polymerase II [ 25 ] , TATA binding protein [ 26 ] , activating transcription factor -2 [ 27 ] , and other components of the basal transcriptional machinery [ 28, 29 ] . HBxAg also binds to an ultraviolet -induced DNA binding protein involved in DNA repair [ 30 ] , and disrupts p53 / excision -repair cross -complementing type 3 protein complexes [ 31 ] , which may disrupt transcription coupled repair, suggesting that HBxAg may promote the accumulation of mutations. In addition, HBxAg binds to and inactivates the negative growth regulators p53 [ 31, 32 ] and p55 sen [33] , as well as decrease the expression of the cyclin -dependent kinase inhibitor p21 WAF1 / CIP1 / SDI1 [ 34 ] and the translation initiation factor sui1 [ 35 ] , both of which also negatively regulate cell growth. Hence, there are multiple pathways whereby HBxAg may alter cellular gene expression. It is likely that these alterations contribute importantly to hepatocarcinogenesis, because HBxAg regulates apoptosis [ 36 -38 ] , mediates resistance to anti -Fas killing [ 39 ] , stimulates cell cycle [ 40 ] , and promotes survival in serum -free medium [ 39 ] . With few exceptions, the natural effectors of HBxAg that promote tumor development have not been identified or well characterized. For example, HBxAg appears to upregulate the expression of insulin -like growth factor 2 ( IGF -2 ) and the IGF -1 receptor in HCC [ 41, 42 ] . Given that the IGF -1 receptor binds to both IGF -1 and -2, it is possible that HBxAg may set up an autocrine loop that enhances cell growth. HBxAg also reportedly trans -activates c -jun, alphafetoprotein, and the pancreatic secretory trypsin inhibitor in reporter gene assays [ 43, 44 ] , but it is not known whether these events occur in vivo. To systematically identify natural effectors of HBxAg, experiments were designed to test the hypothesis that the introduction of HBxAg into HepG2 cells is associated with the altered expression of selected cellular proteins. This work identifies and characterizes one of the HBxAg upregulated genes ( URG ), referred to as URG4, which accelerates cell growth and promotes tumor formation.
Materials and Methods

Cell Lines and Tissue Culture Conditions
The human hepatoblastoma cell line, HepG2 [ 45 ] ( ATCC, Manassas, VA ), was cultured on type -1 rat tail collagen ( Becton Dickinson, Franklin Lakes, NJ ) -coated tissue culture dishes or plates. Cells were grown in Earle's modified Eagle's medium supplemented with 10% heat -inactivated fetal calf serum ( FCS ), 100 M minimal essential medium non -essential amino acids, 1 mM sodium pyruvate, as well as standard concentrations of penicillin plus streptomycin.
HepG2.2.2.15 cells ( a kind gift from Dr. George Acs, Mount Sinai School of Medicine ), which support HBV replication [ 46 ] , and the retrovirus packaging cell line, PA317 [ 47 ] , were also grown in the same conditions.
Plasmids
The retroviral plasmid, pSLXCMVneo, was used to clone the HBV X gene or the bacterial chloramphenicol acetyltransferase ( CAT ) gene sequences, exactly as described [ 33, 48 ] . To verify correct cloning, DNA samples were prepared by using Wizard Plus Minipreps DNA Purification Systems ( Promega, Madison, WI ) and then sequenced in the DNA sequencing facility at the Kimmel Cancer Institute of Thomas Jefferson University.
pcDNA3 ( Invitrogen, SanDiego, CA ) was used to clone full -length upregulated gene, clone 4 ( URG4 ) cDNA under the control of the immediate early CMV promoter and also used for the cloning of the HBx open reading frame, as described [ 35 ] .
Establishment of HBxAg -Positive and -Negative HepG2 Cells
Recombinant retroviruses encoding HBx ( from pSLX-CMV -HBx ) or CAT ( from pSLXCMV -CAT ) were prepared [ 49 ] , titered, and then used to transduce separate cultures of HepG2 cells, as described [ 48 ] . Cultures were then selected in G418 for 14 days to maximize the fraction of cells producing HBxAg or CAT. Standard CAT assays were performed on HepG2CAT lysates using 14 C -chloramphenicol, and acetylated forms were separated by thin -layer chromatography [ 35, 48 ] . Lysates prepared from 5Â10 6 HepG2X cells were assayed for HBxAg by Western blotting with a mixture of HBx peptide antibodies using previous published procedures [ 35, 48 ] .
Polymerase Chain Reaction ( PCR ) Select cDNA Subtraction, Cloning, Sequencing, and Identification of a cDNA from a Putative HBxAg Effector The differences in gene expression, which distinguish HepG2X from HepG2CAT cells, were determined by using a commercially available subtraction hybridization approach ( the PCR -select cDNA subtraction kit from Clontech, Palo Alto, CA ) according to the instructions provided by the manufacturer, with minor modifications [ 48 ] . The PCR fragments corresponding to differentially expressed mRNA were cloned, sequenced, and compared to existing sequences in GenBank. One of these differentially expressed PCR fragments, initially designated as URG4, was chosen for further characterization.
Cloning and Sequencing the Full -Length URG4 cDNA
The full -length cDNA clone containing the URG4 sequences was obtained by the rapid amplification of 5 0 and 3 0 cDNA ends PCR method using the Marathon cDNA Amplification Kit ( Clontech ) as described [ 48 ] . Briefly, one 3 0 and one 5 0 gene specific primers were synthesized. By using these gene -specific primers together with an adaptor primer, PCR was performed with human placental cDNA as template to get the 3 0 or 5 0 cDNA -specific products in separate amplification reactions. The products were cloned into pT7Blue( R ) T vector ( Novagen, Madison, WI ) and sequenced. The appropriate 3 0 and 5 0 gene -specific fragments were then digested with NotI and BclI restriction enzymes and cloned into pcDNA3 ( Invitrogen ) at the chosen sites. The integrity of the full -length clone was verified by DNA sequencing. The full -length sequence was compared to those for homology to known genes in NCBI -GenBank using the nucleotide Basic Local Alignment Search Tool.
Preparation and Use of URG4 Antisera
The full -length cDNA from URG4 was used to deduce the corresponding amino acid sequence using the TRANSLATE program. Hydrophilic and potentially antigenic peptides were deduced from the PEPTIDESTRUCTURE and PLOT-STRUCTURE programs [ 50 ] and made by solid phase peptide synthesis in the Peptide Synthesis Facility on campus. Two peptides, which span inclusive residues 460 -483 ( 24 amino acids ) and 821 -838 ( 18 amino acids ), were coupled to keyhole limpet hemocyanin carrier and used to raise antisera in New Zealand rabbits ( two rabbits / peptide ), as described [ 51 ] . Antisera were initially characterized by specific enzyme -linked immunosorbent assays. For Western blotting, each antiserum was used at a dilution of 1:1000, and blotting was conducted by using a mixture of antisera from both specificities. Western blots for -actin were performed as an internal ( sample loading ) control using commercially available antibody ( Ab -1; Oncogene Research Products, Cambridge, MA ), as described [ 35 ] . Horseradish peroxidase -conjugated goat anti -rabbit Ig ( Accurate, Westbury, NY ) and ECL substrate ( Amersham, Arlington Heights, IL ) were used for detection.
Immunohistochemical staining was performed on slides prepared from formalin -fixed, paraffin -embedded tissues using the Vectastain Elits avidin -biotin -complex Kit according to manufacturer's instructions ( Vector laboratories, Burlingame, CA ) with minor modifications [ 14 ] . A mixture of rabbit antibodies raised against URG4 ( each at 1:4000 dilution ) or HBxAg ( used at a dilution of 1:8000 ) synthetic peptides were used as primary antibodies. Biotinylated antirabbit Ig was used as secondary antibody, and diaminobenzidine was used as substrate for detection. Preimmune serum or preincubation of primary antibodies with an excess of the corresponding synthetic peptide( s ) ( 25 g of each peptide for 1 hour at 378C ) served as controls. For HBxAg staining, uninfected liver was used as an additional control. Immunohistochemistry was evaluated independently by two pathologists counting stained and total hepatocytes in five random fields per slide by light microscopy at a magnification of Â200.
Construction of URG4 -Overexpressing HepG2 and Control Cells
To study the properties of URG4 compared to HBxAg on the cellular level, separate cultures of 1Â10 6 HepG2 cells were stably transfected with 10 g of pcDNA3, pcDNA3 -URG4, or pcDNA3 -HBx using SuperFect transfection reagent ( QIAGEN, Valencia, CA ) according to the instructions provided by the manufacturer. Cells were selected with G418 ( 800 g / ml ) for 4 weeks. URG4 and HBx mRNA expression was assayed by Northern blotting, whereas protein expression was characterized by immunostaining or Western blotting [ 35, 48 ] .
RNA Isolation and Northern Blot Analysis of URG4
Total RNA was isolated from HepG2X, HepG2CAT, HepG2.2.15, HepG2 -pcDNA3, or HepG2 -pcDNA3 -URG4 cells using Tri -Reagent ( Molecular Research Center, Cincinnati, OH ). Extracted RNA was precipitated with isopropanol, and then assessed for integrity of ribosomal RNA by agarose gel electrophoresis. RNA samples were then blotted onto nylon membranes ( Hybond -N, Amersham ). Northern blotting was carried out using the URG4 probe obtained from cDNA subtraction that had been labeled by random priming ( Amersham ). Following autoradiographic exposure, membranes were stripped and rehybridized with a radiolabeled glyceraldehyde -3 -phosphate dehydrogenase ( G3PDH ) probe ( Clontech ). The G3PDH signal served to normalize the URG4 mRNA levels following gel scanning.
Patient Samples
Paired tumor and nontumor liver tissues used for analysis were obtained from 23 Chinese and 14 South African patients chronically infected with HBV who had undergone surgery for the removal of their tumors. Additional characteristics of these patients were previously published [ 35, 48 ] . Analogous pieces of uninfected human liver from five Chinese individuals, who were seronegative for HBV, were available to serve as controls. In addition, paired tumor / nontumor from lung, breast, thyroid, spleen, stomach, pancreas, kidney, and sigmoid colon were obtained from patients who had undergone surgery for the removal of their tumors at Thomas Jefferson University Hospital. Formalinfixed, paraffin -embedded tissues were collected from most patients, used for diagnostic purposes, and were then made available for these studies. Use of all tissues for this work was approved by the Institutional Review Board at Thomas Jefferson University.
In Situ Hybridization ( ISH )
The URG4 cDNA fragment obtained from PCR select cDNA subtraction was used as a probe for ISH to validate the RNA subtraction procedure in HepG2X compared to HepG2CAT cells, and to detect URG4 mRNA in tumor, infected liver, and uninfected tissues. ISH was carried out using the Oncor ISH and digoxigenin / biotin detection kits according to the instructions provided by the manufacturer ( Oncor, Gaithersburg, MD ). Criteria used for evaluation were the same as that outlined above for immunohistochemical staining.
Growth of HepG2 -pcDNA3, -pcDNA3 -HBx, or -pcDNA3 -URG4 Cells in Complete or Serum -Free Medium HepG2 cells stably transfected with pcDNA3, pcDNA3 -HBx, or pcDNA3 -URG4 were seeded into six -well plates in duplicate and grown in complete or serum -free medium. The number of viable cells was determined at daily intervals after seeding for up to 5 days by trypan blue staining. Cell viability was independently determined using the modified tetrazolium salt ( MTT ) assay, as described by the manufacturer ( Cell Titer 96 Non -Radioactive Cell Proliferation Assay, Promega ). Results represent three independent experiments, each done in duplicate.
Flow Cytometry
To asses the effect of URG4 on cell growth, 1Â10 2 ) , from tumor samples of two patients ( lanes 3 and 4 ), and from two uninfected liver samples ( lanes 5 and 6 ). The G3PDH controls for lanes 1 -6 are in lanes 7 -12.
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incubated in 10% FCS containing medium, fixed, stained with propidium iodine, and analyzed by the Flow Cytometry Facility at Thomas Jefferson University at 24 and 48 hours time points.
Growth of URG4 -Overexpressing Cells in Soft Agar and in Nude Mice
HepG2 -pcDNA3, HepG2 -pcDNA3 -HBx, and HepG2 -pcDNA3 -URG4 were tested for anchorage -independent growth in soft agar and for tumor formation in nude mice. For growth in soft agar, 1Â10 4 cells / well were seeded in triplicate into six -well plates, and allowed to grow for 21 days. The colonies were then counted under code. For tumorigenicity assays, 1Â10 7 viable cells ( by trypan blue exclusion ) were injected subcutaneously at a single site in nude mice. The mice were observed over 6 weeks for tumor formation. The mice were then sacrificed and the tumors recovered for further analysis. The use of mice for this work was reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University.
Statistical Analysis
The relationship between ISH and protein staining results for URG4, and between URG4 and HBxAg staining, have been evaluated in 2Â2 tables in a two -tailed analysis. The results were significant when P < .05. The mean difference in growth between HepG2 cell stably transfected with pcDNA3, pcDNA3 -HBx, or pcDNA3 -URG4 was analyzed using the Student's t test. A significant difference was recognized when P < .05.
Results
PCR Select cDNA Subtraction and Identification of URG4
It has been proposed that HBxAg trans -activating properties contribute to the altered patterns of host gene expression that is important for the development of HCC [ 7 ] . To test this hypothesis, HepG2 cells were transduced with recombinant retroviruses encoding HBxAg or the bacterial CAT gene. When RNA from these two cultures were compared by PCR select cDNA subtraction, eight up -and two downregulated genes were observed. One of these upregulated genes, URG4, consisted of a cDNA fragment of $1.7 kb in length that was 99% homologous to an uncharacterized segment in the short arm of chromosome 7.
Before characterizing this gene product in detail, this cDNA fragment was used as a probe for ISH and for Northern blot analysis to verify that the subtractive hybridization worked. When this probe was used for ISH on HepG2X cells, the great majority of the cells showed a dark cytoplasmic brown staining ( Figure 1A ). In contrast, ISH on HepG2CAT cells showed faint or no staining ( Figure 1B ) . ISH with an irrelevant probe [ pT7Blue( R ) T ] failed to hybridize to either HepG2X or HepG2CAT cells ( data not shown ). To quantitate the differences in URG4 mRNA levels in HepG2X compared to HepG2CAT cells, the 1.7 -kb URG4 cDNA fragment was used as a probe in Northern blot analysis. A G3PDH probe, which detected an RNA at about 1.3 kb, was used for normalization. The URG4 probe detected a single band of about 3.6 kb in size that is expressed 5.8 ± 0.3 times higher in HepG2X compared to HepG2CAT cells ( Figure 1C ). These combined results verify that the PCR select cDNA subtraction procedure yielded a cDNA fragment that was upregulated in HepG2X compared to HepG2CAT cells. Figure 1D ) from 8 of 14 South African patients ( 57% ) and from 11 of 23 Chinese patients ( 48% ) ( Table 1 ), suggesting that URG4 was expressed in HCC. In nontumor tissue, the URG4 probe also yielded widespread and strong signals ( Figure 1E ) in 13 of 14 South African patients ( 93% ) and in 21 of 23 Chinese patients ( 91% ) ( Table 1 ) . In contrast, faint ISH signals were observed in three of the five livers from uninfected individuals ( 60% ) ( Figure 1F , Table 1 ). ISH of nontumor liver tissue from the same patient in Figure 1E with an irrelevant probe [ pT7Blue( R ) T vector ] yielded no detectable signal ( Figure 1G ), underscoring the specificity of the method. Since the hybridization signals in nontumor liver tissue from many patients in both populations appeared to be more intense than the signals observed in the corresponding tumor cells from the same patients, a more quantitative measure of these differences was obtained by Northern blotting. In samples where intact RNA was obtained, Northern blot analysis showed a single band at about 3.6 kb in extracts from both tumor and nontumor tissue, although the levels in nontumor tissue ( Figure 1H , lanes 1 and 2 ) were up to several fold higher than in corresponding tumor tissue ( Figure 1H, lanes 3 and 4 ) from the same patients. This RNA is the same size as that Figure 1H, lanes 5 and 6 ) , suggesting that the expression of URG4 is higher in infected compared to uninfected tissue, and that it is generally higher in nontumor compared to tumor cells.
Expression of URG4 in
Tumor, Nontumor, and Uninfected Liver If URG4 is an effector of HBxAg that is important for tumor development, then its expression should be upregulated in the livers and / or tumors of HBV carriers compared to liver tissues from uninfected individuals. To test this hypothesis, ISH was performed in tumor and surrounding nontumor liver, as well as in tissues from five uninfected individuals. The URG4 cDNA probe yielded easily detectable signals in tumor cells (). In contrast, lower levels of hybridization were observed in uninfected liver tissues (
Cloning of Full -Length URG4 and Characterization of URG4 Protein Expression
Based on the results of ISH, full -length URG4 cDNA was obtained by rapid amplification of 5 0 and 3 0 cDNA ends, and the full -length cDNA then cloned into pcDNA3. Sequence analysis of URG4 cDNA showed a short 5 0 untranslated region of 13 bases, followed by an open reading frame of 2766 bases that encodes a polypeptide 922 amino acids long with a calculated molecular weight of 103,876 Da ( Figure 2 ) . The 3 0 untranslated region consists of 828 bases, which adds up to 3.607 kb for the full -length URG4 mRNA. This is approximately the size of the RNA detected by Northern blotting in HepG2 cells ( Figure 1C ) and in liver ( Figure 1H ). The URG4 polypeptide did not have any identifiable motifs suggesting function, save the existence of a possible ATP / GTP binding site motif spanning amino acids 690 -697. Functional analysis failed to show that URG4 bound to or hydrolyzed any of the nucleoside triphosphates, suggesting that this putative binding site motif is not active ( data not shown ). When the full -length URG4 sequence was analyzed by the basic local alignment search tool to find homology with known genes, the search again failed to identify URG4 with any previously published sequence.
To determine the patterns of URG4 protein distribution, selected synthetic peptides were made ( Figure 2 ) and used to generate corresponding antibodies in rabbits. Immunohistochemical staining was then carried out with formalinfixed, paraffin -embedded tissue samples from South African and Chinese carriers. Among South African patients, staining was observed with anti -URG4 in tumor tissue from 8 of 14 patients ( 57% ), whereas staining was observed in 11 of 23 tumor samples from Chinese patients ( 48% ) ( Table 2 ). In surrounding nontumor liver tissue, staining with anti -URG4 was observed in 13 of 14 South African patients ( 93% ) and in 21 of 23 Chinese patients ( 91% ) ( Table 2 ) . Staining was exclusively cytoplasmic in tumor and nontumor liver cells from both sets of patients ( Figure 3 ). When URG4 ISH and immunohistochemical results were compared in tumor for both groups of patients, a strong positive correlation was observed ( P < .001 ). Similar results were obtained when these features were compared in nontumor liver from both groups ( P < .001 ), suggesting upregulation of both RNA and protein in the same patients. When staining was conducted in consecutive sections of tumor from individual patients, there was clear colocalization of URG4 ( Figure 3A ) and HBxAg ( Figure 3B ). Preimmune rabbit serum derived from animals that were subsequently immunized with the URG4 synthetic peptides showed no staining on consecutive tissue sections ( Figure 3C ). Identical results were obtained with preimmune serum from rabbits that were later immunized with HBxAg polypeptides ( data not shown, but exactly like Figure 3C ). Analogous results were obtained when staining was performed in infected nontumor liver tissue using anti -URG4 ( Figure 3D ), anti -HBx ( Figure 3E ), or preimmune serum ( Figure 3F ). Statistical analysis independently confirmed the close association between URG4 and HBxAg in nontumor liver ( P < .005 ). When sections from uninfected liver were evaluated, weak staining was observed in the same three of five samples ( Figure 3G ) that also had detectable ISH signals ( Tables 1 and 2 ). Pretreatment of primary antibodies with an excess of the corresponding synthetic peptides eliminated staining ( data not shown ). These results suggest colocalization of URG4 and HBxAg in HCC and surrounding nontumor liver from HBV-infected patients, and that the expression of URG4 was apparently upregulated in infected tissue.
To further explore the tissue distribution of URG4, anti -URG4 was used to stain samples from pancreas, lung, breast, thyroid, spleen, stomach, kidney, and sigmoid colon tissue sections from uninfected patients. Staining was observed in the cytoplasm of up to 10% of ductal epithelial cells from the pancreas ( data not shown ). None of the other uninfected tissues examined had positive staining. URG4 staining was also observed in the tumor cells from a case of poorly differentiated pancreatic cancer, but was absent from tumor samples of the lung ( non -small cell lung cancer ), thyroid ( follicular adenoma ), breast ( invasive intraductal cancer ), sigmoid colon ( moderately differentiated adenocarcinoma ), and kidney ( papillary transition cell carcinoma ) ( data not shown ). In all cases, the results were based on staining a single normal or tumor specimen of each tissue type. These results suggest a restricted tissue and tumortype distribution of URG4 expression.
Construction and Growth of HepG2 Cells Stably
Transfected with pcDNA3 -HBx, pcDNA -URG4, or pcDNA3
To functionally characterize URG4, independent cultures of HepG2 cells were stably transfected with pcDNA3, pcDNA3 -HBx, or pcDNA3 -URG4, and each of the cell lines selected in G418. The levels of URG4 mRNA and protein were then determined in each of the cell lines by Northern and Western blotting, respectively. Parallel analyses were done with HepG2.2.15 cells to assess URG4 levels in the context of virus replication. Northern blot analysis ( Figure 4A ) showed a single band of 3.6 kb in HepG2 -pcDNA3 cells ( lane 1 ), whereas the levels were 2.8 ± 0. . The finding that endogenous URG4 polypeptide comigrates with the in vitro translation product, and that its size based on sodium dodecyl sulfate / polyacrylamide gel electrophoresis is similar to the calculated value for this protein ( 103,876 Da ), suggests that this band is full -length URG4. These results also verify the expression of URG4 at different levels in these cell lines.
Experiments were then designed to ask whether URG4 overexpression altered cell growth and survival. When these cell lines were grown in tissue culture medium containing 10% FCS ( Figure 4C ) or in serum -free medium ( Figure 4D ), HepG2 -pcDNA3 -HBx cells grew faster than HepG2 -pcDNA3 cells. Statistical analysis showed a significant difference in medium containing 10% FCS on days 2 ( P = .027 ), 3 ( P = .01 ), 4 ( P = .006 ), and 5 ( P = .002 ), and in serum -free medium on days 2 ( P = .008 ), 3 ( P = .025 ), 4 ( P = .004 ), and 5 ( P = .002 ). HepG2 cells that overexpressed URG4 also significantly stimulated the growth in medium containing 10% FCS on days 2 ( P = .033 ), 3 ( P = .022 ), 4 ( P = .012 ), and 5 ( P = .005 ) compared to HepG2 -pcDNA3 controls. HepG2.2.15 cells, which also had elevated URG4 ( Figure 4B ), grew significantly faster than control cells on days 2 -5 ( .02 < P < .03 ), although slower than HepG2 -pcDNA3 and HepG2 -pcDNA3 -HBx on days 4 and 5 ( Figure 4C ). When HepG2 -pcDNA3 -URG4 cells were grown in serum -free medium, significant growth stimulation was observed at days 4 ( P = .003 ) and 5 ( P = .002 ) compared to HepG2 -pcDNA3 cells ( Figure 4D ). URG4 also stimulated growth on days 2 ( P = .041 ) and 3 ( P = .046 ) compared to control cells, although these increases were near the limits of statistical significance. These results suggest that URG4 independently stimulates hepatocellular growth in the absence of HBxAg. However, URG4 overexpression did not stimulate the growth of HepG2 cells as much as HBxAg. Statistical analysis showed the differences in this comparison to be of borderline significance ( Figure  4C ). To confirm whether URG4 stimulates cell growth, these cell lines were analyzed by flow cytometry following synchronization in serum -free medium. At 24 hours after the addition of 10% FCS to synchronized cells, 25.8% of HepG2 -pcDNA3 cells were in S phase, whereas 38.5% of HepG2 -pcDNA3 -URG4 -overexpressing cells were in S phase, and the percentage for HepG2 -pcDNA3 -HBx cells was 45.1% ( Figure 5 ). Again, the difference between control cells and URG4 -overexpressing cells was statistically significant ( P = .006 ), as was the relationship between control and HepG2 -pcDNA3 -HBx cells ( P = .002 ). 
Growth in Soft Agar and Tumor Formation
The URG4 -mediated stimulation of HepG2 growth in culture prompted the design of additional experiments to test whether this growth stimulation extended to anchorage independence and tumor formation. When these cell lines were seeded into soft agar, HepG2 -pcDNA3 -HBx cells yielded an average of 44 ± 8 colonies, whereas HepG2 -pcDNA3 control cells yielded 10 ± 3 colonies after 21 days ( P < .005 ) ( Table 3 ). In comparison, HepG2 -pcDNA3 -URG4 cells yielded 24 ± 4 colonies, which was significantly higher than control cells ( P < .01 ), but not statistically different than HBxAg -producing cells ( P >.1 ) ( Table 3 ) . Together, these results suggest that URG4 stimulates growth in soft agar, although not as strongly as HBxAg.
When these cell lines were individually injected subcutaneously into the backs of nude mice, the majority of mice developed tumors, but the tumors formed by injection of Figure 5 . Flow cytometry of HepG2 -pcDNA3 ( panels A and B ), HepG2 -pcDNA3 -URG4 ( panels C and D ), and HepG2 -pcDNA3 -HBx ( panels E and F ) cells at 24 hours ( panels A, C, and E ) and 48 hours ( panels B, D, and F ) after synchronization and addition of 10% FCS. The results shown here illustrate one of the three independent analyses each done in duplicate. HepG2 -pcDNA3 -URG4 became palpable by 23 ± 3 days postinjection compared to control cells, which became palpable by 43 ± 5 days postinjection ( P < .005 ) ( Table 4 ). The tumors also grew to an average of twice the size in mice injected with HepG2 -pcDNA3 -URG4 compared to control cells, although these differences did not reach statistical significance ( P >.4 ) ( Table 4 ) . Interestingly, HepG2 -pcDNA3 -HBx cells also yielded accelerated tumor growth, and larger tumor size compared to control cells, although only tumor onset was statistically significant ( P < .02 ) ( Table 4 ). These results demonstrate that URG4 promotes tumor cell growth in vivo.
Discussion
The alteration of host gene expression by HBxAg may be important for the pathogenesis of chronic liver disease and the development of HCC, by activating several signal transduction pathways and affecting the activation of selected transcription factors that regulate proliferation, differentiation, transformation, and invasive growth [ 5, 7 ] . In this work, experiments were designed to test the hypothesis that introduction of HBxAg into HepG2 cells is associated with altered patterns of host cell gene expression that regulate cell growth and survival. This report describes the isolation and partial characterization of a novel gene, URG4, which is upregulated in the presence of HBxAg, and may contribute importantly to the development of HCC by promoting hepatocellular growth and survival. Based on PCR select cDNA subtraction of RNA obtained from HBxAg -positive and -negative cell lines, a cDNA fragment, designated URG4, appeared to be expressed at higher levels in HBxAg -positive compared to negative cells. This was confirmed by ISH using the cells from each of these lines ( Figure 1, A and B ) and quantitated by Northern blotting ( Figures 1C and 4A ) as well as Western blotting ( Figure 4B ). These findings validate the subtraction methodology used and show that URG4 is upregulated at the RNA and protein levels in the presence of HBxAg. To determine whether URG4 was upregulated in HBV infected compared to uninfected liver, ISH was performed on fresh frozen sections from HCC, nontumor liver, and uninfected liver samples. Strong hybridization signals were detected in nontumor liver samples from HBV-infected patients with HCC, at lower levels in the tumor cells from some of the same patients, and at still lower levels in uninfected liver tissue ( Figure 1, D -G ) . Again, these results were confirmed and quantitated by Northern blot analysis ( Figure 1H ) , and suggest that URG4 was differentially expressed at the RNA level in infected compared to uninfected liver tissue. At the protein level, immunohistochemical staining was noticeably stronger among infected tumor and nontumor specimens compared to uninfected liver ( Figure 3 ) suggesting again that URG4 expression is upregulated in infected compared to uninfected liver. The fact that HBxAg staining strongly correlated with that of URG4 ( Figure 3 ) in many patients from two geographically disperse populations, not only suggests that URG4 upregulated expression occurs commonly in the liver and tumor of carriers with HCC, but also that URG4 is likely to be a natural effector of HBxAg in vivo. This is further strengthened by the observation that URG4 polypeptide was upregulated in HBxAg -positive cells, and in cells replicating HBV compared to HBxAg -negative control cells ( Figure 4B ).
HBxAg stimulates cell growth and survival in a number of published reports [ 5,16 -18,40,48 ] , and such a property is likely to contribute importantly to the development of HCC. Hence, if URG4 is a natural effector of HBxAg in chronic infection, it should have at least some of the functions associated with HBxAg. For example, the finding that HBxAg stimulates growth in medium containing 10% serum as well as in serum -free medium, and that URG4 also stimulates growth and survival under these conditions ( Figure 4 , C and D ), is consistent with the hypothesis that URG4 is an effector of HBxAg that carries out, at least in part, an HBxAgassociated activity that may contribute to the development of HCC. The fact that URG4 overexpression only partially stimulates cell growth and survival under these conditions is consistent with the probability that other HBxAg effectors, such as the recently published URG7 [ 48 ] , may also contribute importantly to hepatocellular growth and survival. In this context, it will be important to determine whether the URG4 stimulation of cell growth and survival is associated with the constitutive activation of one or more signal transduction pathways that are known to be activated by HBxAg and that are associated with the HBxAg -mediated stimulation of cell growth [ 7, 21, 40 ] . HBx stimulates cell cycle progression by shortening the emergence of cells from quiescence ( G 0 ) and entry into S phase and also accelerating transit through checkpoint controls at G 0 /G 1 and G 2 /M [ 40 ] . The data from flow cytometry with URG4 -overexpressing cells ( Figure 5 ) is consistent with this possibility. In addition, by disturbing the regulation of the checkpoint controls, HBx ( through URG4? ) may contribute to genetic instability, in which unrepaired transforming mutations would accumulate during the pathogenesis of HCC [ 40 ] .
HBxAg is also known to transform cells in vitro [ 18 ] and give rise to HCC in selected strains of X transgenic mice characterized by sustained, high levels of HBxAg expression [ 16, 17 ] . To test whether URG4 contributes to hepatocarcinogenesis, URG4 -overexpressing cells were seeded into soft agar, and tested for anchorage -independent growth, which is an important, although not invariable feature of the transformed cell phenotype. The finding that oncogenes often stimulate anchorage -independent growth when introduced into cells [ 52, 53 ] , and that URG4 stimulates anchorage -independent growth in soft agar ( Table 3 ), suggests that URG4 may be an oncogene operative in hepatocarcinogenesis. This is further supported by the finding that URG4 stimulates tumor formation in nude mice ( Table 4 ) . In summary, HBxAg stimulates the expression of an oncogene in preneoplastic liver that promotes growth factorindependent survival, anchorage -independent growth, and accelerates tumor formation. Given that this upregulation occurs in many patients from two different parts of the world further suggests that URG4 is a natural effector of HBxAg that contributes frequently and importantly to the mechanism of HBxAg -mediated hepatocellular transformation.
